ArticleFrontiers in neurology2025
Repetitive transcranial magnetic stimulation elevates the serum levels of neurotrophic factors and serotonin and its metabolites in patients with ischemic stroke.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interventions for post-stroke cognitive impairment: a systematic review of neuroplastic mechanisms, comparative efficacy, and multimodal approaches.Frontiers in neuroscience · 2026Pooled it
- Plasma Tryptophan Hydroxylase 1 Activity-related Metabolic Markers and Stroke Risk: A Nested Case-control Study.Translational stroke research · 2026Article
- Neuromodulation and rehabilitation of post-stroke cognitive impairment: challenges and prospects.Frontiers in psychiatry · 2026Review
- Recent Advances in Repetitive Transcranial Magnetic Stimulation for the Treatment of Post-Stroke Cognitive Impairment.CNS neuroscience & therapeutics · 2025Review
- Exploring NMDAR pathways in ischemic stroke: implications for neurotoxic and neuroprotective mechanisms and therapeutic strategies.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Repetitive transcranial magnetic stimulation (rTMS) can effectively treat cognitive impairment in stroke patients; however, its mechanism of action remains unclear. The aim of this study was to investigate whether rTMS improves cognitive function by regulating the levels of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), 5-hydroxytryptamine (5-HT), and 5-hydroxyindoleacetic acid (5-HIAA). Methods: In a 4-week study, 70 patients with ischemic stroke were randomly assigned to two groups: one received rTMS ( Results: The levels of BDNF and NGF were higher in the rTMS group than in the sham group ( Conclusion: Our results showed that the BDNF, NGF, 5-HT, and 5-HIAA levels were upregulated after the rTMS treatment, which likely contributed to improvements in cognitive function and quality of life in the patients with stroke. Clinical trial registration: https://www.chictr.org.cn/showproj.html?proj=216761, ChiCTR2400082383.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.